EBOS Group Ltd
NZX:EBO
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
NZ |
EBOS Group Ltd
NZX:EBO
|
6.7B NZD | 10 | ||
US |
Mckesson Corp
NYSE:MCK
|
71.4B USD | 20.5 | ||
US |
Cencora Inc
NYSE:COR
|
44.2B USD | 16.7 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 21 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.7B USD | 7.6 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.5B USD | 7.3 | ||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
70.4B HKD | 8.2 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -236.8 | |
IT |
Amplifon SpA
MIL:AMP
|
7.7B EUR | 50.1 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
58.8B CNY | 24.8 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
53B CNY | 5.8 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.